Inactive Instrument

Other languages Urovant Sciences Ltd.

Equities

UROV

BMG9381B1081

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Urovant Sciences and Pierre Fabre Médicament Enters into Exclusive License Agreement	05/07/22
Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting	15/05/22
Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints	13/05/22
Urovant Sciences Announces the Publication of A New, Post-Hoc Analysis of Data from the Phase 3 EMPOWUR Trial of GEMTESA 75 Mg in the International Journal of Clinical Practice	19/04/22
Urovant Sciences Announces Management Changes	04/04/22
Urovant Sciences : Posts Wider Fiscal Q3 Net Loss	12/02/21
Urovant Sciences Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/02/21
Urovant Sciences : Gets FDA Nod For Overactive Bladder Drug Gemtesa -- Stock Up 3% After-Hours	23/12/20
Urovant Sciences : Says Topline Data From Vibegron Study for Irritable Bowel Syndrome Failed to Meet Primary Endpoint	24/11/20
Urovant Sciences : Reports Positive Data From Study of Vibegron to Treat Overactive Bladder	19/11/20
After Hours Watch List Scorecard: UROV, FTCH, SAVA	13/11/20
Sector Update: Health Care Stocks Finishing Higher This Afternoon	13/11/20
Sector Update: Health Care Stocks Climbing Friday	13/11/20
Sector Update: Health Care	13/11/20
Midday Report: Wall Street Firmer After Choppy Trading Week	13/11/20
Sector Update: Health Care Stocks Gain Pre-Bell Friday	13/11/20
Sector Update: Health Care	13/11/20
Urovant Sciences : To Be Acquired by Sumitovant Biopharma for $16.25 Per Share; Stock Soars 91% in Late Trade	12/11/20
Urovant Sciences Ltd. Reports Earnings Results for the Second Quarter Ended September 30, 2020	02/11/20
Urovant Sciences Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2020	13/08/20

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Urovant Sciences Ltd.

Equities

UROV

BMG9381B1081

Other languages

Filters